Alternative splicing modifies the effect of mutations in COL11A1 and results in recessive type 2 Stickler syndrome with profound hearing loss. by Richards, Allan et al.
ORIGINAL ARTICLE
Alternative splicing modifies the effect of mutations
in COL11A1 and results in recessive type 2 Stickler
syndrome with profound hearing loss
Allan J Richards,1,2 Gregory S Fincham,3 Annie McNinch,1,2,3 David Hill,2
Arabella V Poulson,3 Bruce Castle,4 Melissa M Lees,5 Anthony T Moore,6
John D Scott,3 Martin P Snead3
▸ Supplementary figure S1
published online only. To view


















Department, Royal Devon &
Exeter NHS Foundation Trust,
Exeter, UK
5Department of Clinical
Genetics, North East Thames
Regional Genetics Service,






Dr Martin Snead, Vitreoretinal
Service, Addenbrooke’s
Hospital, Cambridge University
NHS Foundation Trust, Hills
Road, Cambridge CB2 0QQ,
UK; mps34@cam.ac.uk
Received 11 February 2013
Revised 5 June 2013
Accepted 3 July 2013
Published Online First
6 August 2013
To cite: Richards AJ,
Fincham GS, McNinch A,
et al. J Med Genet
2013;50:765–771.
ABSTRACT
Background Stickler syndromes types 1, 2 and 3 are
usually dominant disorders caused by mutations in the
genes COL2A1, COL11A1 and COL11A2 that encode
the fibrillar collagens types II and XI present in cartilage
and vitreous. Rare recessive forms of Stickler syndrome
exist that are due to mutations in genes encoding type
IX collagen (COL9A1 type 4 Stickler syndrome and
COL9A2 type 5 Stickler syndrome). Recently, recessive
mutations in the COL11A1 gene have been
demonstrated to result in fibrochondrogenesis, a much
more severe skeletal dysplasia, which is often lethal.
Here we demonstrate that some mutations in COL11A1
are recessive, modified by alternative splicing and result
in type 2 Stickler syndrome rather than
fibrochondrogenesis.
Methods Patients referred to the national Stickler
syndrome diagnostic service for England, UK were
assessed clinically and subsequently sequenced for
mutations in COL11A1. Additional in silico and
functional studies to assess the effect of sequence
variants on pre-mRNA processing and collagen structure
were performed.
Results In three different families, heterozygous
COL11A1 biallelic null, null/missense or silent/missense
mutations, were found. They resulted in a recessive form
of type 2 Stickler syndrome characterised by particularly
profound hearing loss and are clinically distinct from the
recessive types 4 and 5 variants of Stickler syndrome.
One mutant allele in each family is capable of
synthesising a normal α1(XI) procollagen molecule,
via variable pre-mRNA processing.
Conclusion This new variant has important
implications for molecular diagnosis and counselling
families with type 2 Stickler syndrome.
INTRODUCTION
Type XI collagen along with type II collagen, forms
the heterotypic fibrillar collagen fibrils found in car-
tilage and vitreous. It is a heterotrimer, encoded by
three genes COL11A1 (MIM 120280), COL11A2
(MIM 120290) and COL2A1 (MIM 120140),1–7 the
latter also encodes the homotrimer type II collagen
that constitutes the major component of these colla-
gen fibrils. Although type XI collagen is a quantita-
tively minor component of the fibrils it has an
important role in regulating fibrillogenesis.8
Mutations of all three genes can result in different
types of Stickler syndrome (MIM 108300, 604841,
184840),9–11 which is usually an autosomal domin-
ant disorder with variable phenotype that includes
myopia, retinal detachment, premature osteoarthritis,
hearing loss, facial dysmorphism and midline clefting
that can manifest as Pierre Robin sequence, or an iso-
lated cleft palate.12 The COL11A2 gene is not
expressed in the eye and mutations in that gene do
not result in an eye phenotype.13 A recessive form of
Stickler syndrome (MIM 614134, 614284)14 15 has
been reported in association with null alleles of type
IX collagen genes (COL9A1 MIM 120210 and
COL9A2 MIM 120260). Type IX collagen connects
heterotypic type II/XI collagen fibrils to other com-
ponents of the extracellular matrix.16 17
A recent systematic review of published informa-
tion on hearing loss in Stickler syndrome18 con-
cluded that more than half of all patients have
some form of hearing loss, but that this may vary
between the different types. Hearing loss is usually
mild to moderate, however when associated with
COL11A1 and COL11A2 it is more common,
more severe and presents at a younger age than for
COL2A1. In the recessive forms, due to mutations
in type IX collagen, the hearing loss is variable and
has been described as mild to severe.14 15
The recessive disorder fibrochondrogenesis (MIM
228520), which is usually lethal, has also been shown
to be due to mutations in COL11A1.19 20 In that dis-
order the mutations are either a combination of null
alleles and missense mutations or biallelic null alleles.
The carrier parents showed only mild clinical features
such as myopia or hearing loss and were not consid-
ered to have Stickler syndrome.
COL11A1, COL11A2 and COL2A1 are all subject
to alternative splicing,21 22 where inclusion or exclu-
sion of exons encoding the N-propeptide region of
the molecules results in isoforms that can vary in
their interaction with other components of the extra-
cellular matrix23 and growth factors such as TGFβ1
and BMP-2.24 As previously demonstrated, mutations
in the alternatively spliced exon 2 of COL2A1 result
in a non-systemic (or predominantly ocular) form of
type 1 Stickler syndrome25 (MIM 609508). Here we
demonstrate that mutations, in two families, affecting
the alternatively spliced exon 9 (also referred to as
exon 8 or variable region 2)26 27 of COL11A1 which
is not expressed in cartilage,28 are modified by the
natural alternative splicing that occurs in this gene.
Open Access
Scan to access more
free content
Richards AJ, et al. J Med Genet 2013;50:765–771. doi:10.1136/jmedgenet-2012-101499 765
Phenotypes
Both cases have a second mutation, but the combination of the two
results in a recessive form of type 2 Stickler syndrome with pro-
found hearing loss, rather than the more severe fibrochondrogen-
esis. In addition, we describe a third family with recessive type 2
Stickler syndrome that have a silent mutation which is variably
spliced and able to express at least some normal α1(XI) collagen.
MATERIALS AND METHODS
Three families referred to the national Stickler syndrome diag-
nostic service for England were assessed clinically and with
informed written consent, subsequently screened for mutations
in COL11A1. The study was approved by the local research
ethics committee.
Gene analysis
The COL11A1 gene was analysed by amplification and sequencing
of all exons as previously described.29 In addition, possible regions
of gene deletion/duplication were examined by multiplex ligation-
dependent probe amplification using commercially available probes
(MRC-Holland, Amsterdam, the Netherlands). The cDNA num-
bering is derived from the COL11A1 transcript NM_001854.3.
The exons are numbered 1–68 as described in the reference
sequences (NM_001854.3, NM_080692.2 and NM_080693.3),
where exons 6, 7 and 9 are alternatively spliced, rather than
numbered as exons 1–67 as in Annunen et al27 Transcript
NM_001854.3 contains exons 6 and 9 (also referred to as exon
6A and 8, respectively) but not exon 7 (also referred to as exon 6B).
Mutation analysis
The effect of sequence variants on pre-mRNA processing was
assessed in silico and functionally. Functional studies were per-
formed using either minigenes as splicing reporters or cultured
cells obtained from a heterozygous carrier. The minigene system
USR1330 consisted of a cassette of four exons (43–46) from the
COL2A1 gene into which a test exon could be inserted to
obtain normal and variant hybrid minigene constructs. These
could then be expressed in cultured mammalian cells. Cultured
dermal fibroblasts obtained from patients were incubated with
and without emetine, an inhibitor of nonsense mediated decay
(NMD). RNA prepared from either transfected or patients’ cells
was analysed by reverse transcription PCR (RT-PCR) as previ-
ously described.30
Sequence variations were analysed in silico, using Alamut V.2.0
(Interactive Biosoftware, Rouen, France), a software package that
uses four different programmes to predict the effect of variants on
pre-mRNA splicing (as previously described)30 and three pro-
grammes to analyse the effect of amino acid changes on protein
function. These are PolyPhen-2, sorting intolerant from tolerant
(SIFT) and align Grantham variation Grantham deviation




RNA isolated from cultured cells of the carrier for the
c.2607A>G, p.Ala869Ala was reverse transcribed with a gene
specific primer and superscript II (Invitrogen, http://www.
invitrogen.com). The relative amount of the G allele was com-
pared with the expression of the A allele by quantitative PCR
using primers located in exon 32 and 33 and fluorescently
labelled cDNA probes specific for each allele. RNA from a
normal individual was used as a positive control for the A allele
and a negative control for the G allele. Each reaction was
performed in triplicate and this was repeated three times.
A chromo4 machine (BioRad, http://www.bio-rad.com) was used
to measure the amount of fluorescence produced from each amp-
lification reaction, and the Opticon-Monitor software (BioRad,
http://www.bio-rad.com) was used to measure the relative differ-
ence in expression between the normal A and mutant G allele.
RESULTS
In each family, two unique mutations/variants were found as
illustrated in figure 1 and online supplementary figure S1.
Family 1
The proband had been born with a cleft palate and subsequently
found to be profoundly deaf with no recordable response from
the left ear up to 100 dB and only a barely recordable response at
250 Hz/100 dB for the right ear. She communicates as an adult
with sign language. Despite being hypermetropic (+3.50DS right,
+4.50DS left) ophthalmological assessment revealed a hypoplastic
vitreous gel architecture,29 without the membranous or beaded
congenital vitreous anomaly. Assessment of her parents revealed
insignificant, age-compatible sensorineural hearing loss for her
mother (25 dB/4000 Hz) and mild to moderate sensorineural
hearing loss in her father (40 dB/1000–4000 Hz). Both parents
had unremarkable vitreous architecture, exhibiting only mild age
related vitreous syneresis. The pedigree is illustrated in figure 1.
Mutations in exon 9 (c.1191delT, p.Asn398Metfs*19) and
exon 58 (c.4259G>T, p.Gly1420Val) were found in the
proband. Analysis of the parents’ DNA showed that the
proband had inherited one mutation from each parent. The
c.1191delT mutation has been previously reported, but errone-
ously located in exon 6 instead of exon 9.31 Because skipping of
exon 9 would leave the message inframe and a functional colla-
gen expressed, studies using RNA obtained from cultured
Figure 1 Inheritance patterns of mutations. The pedigrees indicate
the inheritance of each mutation in three different families. Solid
squares/circles indicate individuals with type 2 Stickler syndrome.
Vertical bars are carriers that had minor clinical signs associated with
Stickler syndrome or a normal clinical appearance.
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dermal fibroblasts with the exon 9 mutation (c.1191delT) were
used to assess whether any nonsense associated exon skipping
resulted from this mutation. Cultured dermal fibroblasts which
constitutively express the alternatively spliced exon 9 were
treated with a nonsense mediated decay inhibitor. Amplification
of cDNA (figure 2A), showed that the uninhibited cells pro-
duced a homozygous cDNA sequence which included exon 9,
and since nonsense associated exon skipping would have
resulted in a heterozygous sequence, this demonstrated that only
the normal allele was expressed. Cells treated with the NMD
inhibitor expressed both alleles, thereby confirming that the
mutant allele would normally be naturally degraded by this cel-
lular RNA quality surveillance system. However in tissues not
expressing exon 9 the mutation would be naturally removed
from the mature transcript. The p.Gly1420Val mutation dis-
rupted the Gly-Xaa-Yaa amino acid repeat sequence of the colla-
gen molecule, which is typical of pathogenic mutations in
collagen molecules, and was predicted to be pathogenic by all
three protein analysis tools in Alamut.
Family 2
Two young boys, with severe and profound hearing loss, pre-
sented with parents who exhibited only mild clinical signs asso-
ciated with Stickler syndrome, but were not considered to have
the disorder. The proband was referred at age 20 months
having been born with congenital high myopia (−7DS bilat-
erally), Pierre Robin sequence and profound hearing loss
(90 dB), for which he had been treated with bilateral cochlear
implants. His newborn brother (18 days old) also had Pierre
Robin sequence and auditory brainstem assessment demon-
strated no recordable responses at over 95 dB; typanometry
was normal. Audiometry findings were confirmed on retesting
and cochlear implants are planned. Their father had a high
arched palate and mild, asymptomatic high tone hearing loss.
The mother exhibited mild, asymptomatic hearing loss
(35 dB/1000–2000 Hz); she also reported a history of hearing
loss in her family. She had healthy compact vitreous gel archi-
tecture. The pedigree is illustrated in figure 1. Analysis of
COL11A1 identified a frameshift mutation c.1421dupC,
p.Gly475Argfs*9 in exon 13 and a sequence variant
c.991-24A>G in intron 8 which was absent from the dbSNP
(single nucleotide polymorphism) variation database (http://
www.ncbi.nlm.nih.gov/snp). In silico analysis of this variant
predicted that it created an alternative exon 9 acceptor splice
site. It was also analysed functionally using minigenes, by
cloning the normal and variant alleles into the splicing reporter
USR13. This vector has been successfully used to assess other
non-AG-GT splice site mutations that result in exon skipping
and dominant type 2 Stickler syndrome (see online
supplementary figure S2), including one (c.1845+5G>A)
known to result in exon skipping in cultured cells.29 The normal
and mutant minigenes produced a small amount of exon skip-
ping, which reflected that this exon is alternatively spliced.
However, the full length mutant cDNA appeared larger than the
normal cDNA. This was confirmed by specifically amplifying
and sequencing transcripts which included the 255 bp exon 9
(figure 2, see online supplementary figure S2B). The mutant
transcript contained an insertion of an additional 23 bp at the
start of exon 9 which corresponded to the creation of an
acceptor splice site by the mutation, as predicted by in silico ana-
lysis. It caused a shift in the reading frame and a downstream
premature termination codon. Despite the normal acceptor
splice site being present, it was not used in the minigene experi-
ments, as the sequence obtained from the variant clone was
homozygous (figure 2B). Because exon 9 is not expressed in all
tissues (NM_080630.3, transcript variant C) this mutation, like
the c.1191delT mutation, would be naturally removed from
transcripts in those tissues and have no effect.
Figure 2 Analysis of exon 9 mutations c.1191delT and c.991-24A>G
by RT-PCR. RNA from a cell line heterozygous for the c.1191delT
mutation was analysed by RT-PCR and sequenced (A). cDNA from cells
incubated with emetine to inhibit NMD (−NMD) had the frameshift
mutation, whereas cDNA from uninhibited cells (+NMD) had a
homozygous sequence from the normal allele only. COL11A1 exon 9,
including 682 bp of surrounding intron sequence, was amplified from
genomic DNA containing the c.991-24A>G mutation (B). This was
cloned into the splicing reporter USR13, between COL2A1 exons 44
and 45. Normal and mutant alleles were expressed in MIO-M1 cells,
with the resulting RNA analysed by RT-PCR and sequencing (B). The
variant cDNA had an additional 23 bp, which corresponded to the
sequence from COL11A1 IVS8 and a de novo acceptor splice site
created by the mutation. Green=A, red=T, blue=C, black=G.
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Family 3
The proband was a young girl (figure 3), born prematurely at
32 weeks and tube fed for 4 weeks, but without any evidence of a
cleft palate. Hearing loss was diagnosed at 5 weeks of age, later
being confirmed with pure tone audiometry which showed severe
mixed conductive and sensorineural hearing loss from 250 Hz–
8000 Hz with flat tympanometry. At 2 years of age concerns about
visual development and a very pale fundal reflex led to referral for
investigation of a possible retinal dystrophy. Refraction under
cycloplegia revealed high myopia (−12:50DS right, −12:50DS
left) and slit-lamp examination noted the type 2 beaded vitreous
anomaly, associated with mutations in COL11A1.29 Despite the
high refractive error, the discs were of normal size and configur-
ation. A clinical diagnosis of probable type 2 Stickler syndrome
was made. Full field electroretinogram, pattern reversal visual
evoke potential and flash visual evoke potential were normal. Both
parents exhibited healthy compact vitreous gel architecture and no
evidence of hearing loss on audiology testing. The proband exhib-
ited clinical joint laxity, but with no evidence of dysplastic changes
of the hips or pelvis visible on radiology. Analysis of COL11A1
identified a silent variant c.2607A>G, p.Ala869Ala and a missense
alteration c.5398G>T, p.Gly1800Cys. Both of these changes are
novel and were absent from the dbSNP variation database (http://
www.ncbi.nlm.nih.gov/snp). Analysis of the parents’ DNA showed
that the silent variant was inherited from the father and the mis-
sense change from the mother. Analysis in silico predicted that the
silent DNAvariant created a donor splice site within exon 33 and
also a potential binding site for the splicing factor SRp55. Using
RNA obtained from the father’s cultured dermal fibroblasts,
RT-PCR demonstrated three splice isoforms (figure 4). First, RNA
from cells uninhibited for NMD had the normal and variant
sequence, demonstrating that the variant allele could be spliced
normally, although there appeared to be unequal peak heights in
the sequence chromatogram (figure 4). Using RNA from cells
where NMD was inhibited, the use of the variant sequence as a
donor splice site was observed by sequencing in the reverse
Figure 3 Facial photographs of a child with recessive type 2 Stickler
syndrome. The child has c.2607A>G, p.Ala869Ala and c.5398G>T,
p.Gly1800Cys mutations in COL11A1. The p.Gly1800Cys was inherited
from her mother who is also shown.
Figure 4 RT-PCR analysis of the c.2607A>G, p.Ala869Ala mutation.
Cultured cells from a heterozygous carrier were incubated with (−NMD)
or without (+NMD) emetine to inhibit nonsense mediated decay. NMD
was also inhibited in a normal cell line as a control. RNA was analysed
by RT-PCR and sequenced in the forward (A) and reverse (B) directions.
Text sequence represents the sequence seen in uninhibited cells (upper)
and the additional sequence obtained from inhibited cells (lower). In
(A) an additional sequence was located between exons 32 and 33 (in
bold type), which corresponded to a pseudoexon in intron 32. In the
reverse direction, the mutant sequence (arrowed) was present in cDNA
from uninhibited (+NMD) cells. When nonsense mediated decay was
inhibited an additional transcript was seen which corresponded to the
use of the GTGCAC sequence (in bold) as a donor splice site.
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direction, confirming the in silico prediction. In addition to the
variant creating a donor splice site in the exon, sequencing in the
forward direction also identified insertion of 16 nucleotides
between exons 32 and 33. An examination of intron 32 showed
that the inserted sequence was present at c.2557–186 to −171, it
was preceded by a cag sequence and followed by the sequence
gtaagt, which matched consensus acceptor and donor splice sites,
respectively. Therefore the inserted sequence represented a pseu-
doexon which was activated by the c.2607A>G variant. Both of
the misspliced transcripts resulted in frameshifts and premature
termination of translation, reducing the level of expression from
the mutant G allele. Quantitative RT-PCR indicated that the
expression of the G allele was approximately 42± 3.5% of the
normal A allele (data not shown), meaning that the misspliced
transcripts represented around 58% of transcripts from the G
allele.
The missense change inherited from the mother changed a
conserved glycine to cysteine in the C-propeptide region of the
molecule (figure 5). Disruption to the pattern of cysteines in the
C-propeptide of collagen molecules has been found in various
other collagenopathies32 and in silico analysis predicted that the
amino acid change was damaging.
DISCUSSION
Stickler syndrome is usually a dominant disorder due to muta-
tions in the collagen genes COL2A1, COL11A1 and COL11A2.
Although there are rare recessive forms, these have all been
reported in consanguineous families where the mutations have
been homozygous.14 15 31 33 Here we report three non-
consanguineous families with a novel recessive form of type 2
Stickler syndrome, without consanguinity to assist interpretation
of the sequence variants detected. In all three, the phenotype is
different from that documented with recessive type IX collagen
mutations14 15 and is characterised by unusually severe/pro-
found hearing loss. In two children this required cochlea
implants, while an adult patient communicates by sign language.
The majority of mutations that result in dominant type 2
Stickler syndrome have been found to affect consensus splice
sites in the COL11A1 gene and result in exon skipping. Because
of the nature of exons in collagen genes, which typically encode
a complete set of Gly-Xaa-Yaa amino acid repeat sequences,
such mutations result in shortened α1(XI) procollagens that
exert a dominant negative effect upon normal gene products
with which they coassemble. Other mutations alter obligate gly-
cines that must occur at every third position in the 1014 residue
collagen triple helical domain.
Further phenotypes associated with mutations in COL11A1 are
Marshall syndrome and fibrochondrogenesis. Marshall syndrome
is a differential diagnosis to type 2 Stickler syndrome, it results
mainly from exon skipping mutations of COL11A1 and differs in
the severity of facial features that may be present.27
Fibrochondrogenesis was first characterised molecularly by
Tompson et al,19 who found heterozygous null alleles inherited
along with a substitution of an obligate glycine on the second
allele. Later Akawi et al20 characterised two families who both had
biallelic null mutations. Here we have demonstrated how, due to
alternative splicing, which can be either natural or pathogenic in
origin, similar null/missense or biallelic null mutations result in
Stickler syndrome rather than fibrochondrogenesis (table 1).
Exon 9/intron 8 mutations
The c.1191delT mutation seen in family 1 has been previously
reported in a homozygous state,31 emphasising the recessive
nature of this mutation. However, Alzahrani et al31 erroneously
located the mutation in exon 6. As in family 1 the patient
described by Alzahrani et al31 had hearing loss, cleft palate but
not myopia, although vitreoretinal degeneration was present in
both. Alzahrani et al suggested that the resulting Stickler pheno-
type questioned whether fibrochondrogensis was simply a case
of COL11A1 deficiency, and failed to consider that in fact exon
9 is naturally alternatively spliced26–28 and that only transcripts
expressing this exon (NM_001854.3, NM_080692.2 transcript
variants A and B) will be affected. Whereas transcript variant C
(NM_080693.3) expressed in cartilage will not be altered. The
examples of recessive Stickler syndrome that we describe here
demonstrate that their premise is likely to be incorrect, and that
the recessive Stickler syndrome phenotype is more probably due
to the ability to synthesise normal α1(XI) collagen molecules
because the mutations are removed by naturally occurring alter-
native splicing.
The expression of COL11A1 exon 9 in rat long bones is similar
to the expression of the long form of type II collagen, that con-
tains the region encoded by exon 2 of COL2A1.34 Both are
present in immature chondrocytes but disappear as these cartilage
precursors differentiate and mature. This would explain why the
resulting phenotype in these individuals presented as Stickler syn-
drome rather than fibrochondrogenesis. As with the mechanism
Figure 5 Multiple sequence alignment of the C-termini of the fibrillar
collagens. Amino acids identical in at least seven of the nine protein
sequences are in bold type. The position of the p.Gly1800Cys mutation
is indicated.
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that removes mutations in exon 2 from COL2A1 and results in a
non-systemic form of Stickler syndrome,25 so the natural alterna-
tive splicing of COL11A1 exon 9 modifies the effect of the muta-
tions, consequently the severity of abnormal skeletal development
is reduced. However, this exon is expressed in Meckel’s cartilage26
which gives rise to the malleus and incus of the inner ear, in add-
ition to the anterior ligament of the malleus tympanic plate,35
which is likely to explain why there is a more severe hearing than
skeletal phenotype in these patients.
Like the c.1191delT mutation the c.991-24A>G mutation in
intron 8, seen in family 2, will only affect tissues that express exon
9. Although not obviously pathogenic a combination of functional
minigene analysis, in silico analysis, absence from the variation
sequence databases and inheritance patterns, together indicate the
pathogenic nature of this mutation. The family with the
c.991-24A>G mutation also had a frameshift c.1421dupC muta-
tion, predicted to result in two null alleles, similar to the families
described by Akawi et al,20 except that here one (c.991-24A>G) is
modified by alternative splicing of exon 9, whereas those causing
fibrochondrogenesis affect constitutive exons.
Glycine substitution
As with the cases of fibrochondrogenesis described by Tompson
et al,19 one patient characterised here possesses similar null/mis-
sense mutations, but has Stickler syndrome instead. The missense
mutation p.Gly1420Val was coinherited with a null allele due to a
mutation (c.1191delT) in the alternatively spliced exon 9. The
missense mutation was also present in the patient’s mother who
exhibited only age-related hearing loss and no other clinical signs
usually associated with mutations of COL11A1. This may be sur-
prising, however, in other fibrillar collagens the substitution of
obligate glycines can result in a wide range of phenotypic severity
from lethal to mild, with the genes for type I collagen and osteo-
genesis imperfecta being the most studied.36 To date only eleven
glycine substitutions have been described in COL11A1, and so the
range of possible resulting phenotypic variation is currently
unknown and difficult to predict from any particular missense
mutation. The heterozygous carriers of similar glycine substitu-
tions described by Tompson et al19 were also not considered to
have Stickler syndrome and presented with only mild phenotypes,
such as myopia or hearing loss. It would therefore appear that as
with the quantitatively major collagens such as type I and type II
collagen, substitutions of an obligate glycine in α1(XI) collagen
can result in a spectrum of phenotypes, some resulting in Stickler
syndrome, while others may produce only subtle clinical features
not recognised as that disorder. The report of recessive Marshall
syndrome37 in a consanguineous family with a homozygous
glycine substitution in α1(XI) collagen supports this conclusion. In
heterozygous cases of recessive type 2 Stickler syndrome there is a
risk that a glycine substitution may be mistaken for dominant
mutation, and the recessive nature of the change overlooked.
Silent mutation
As has previously been seen in COL2A1 and type 1 Stickler syn-
drome,29 here a silent mutation in COL11A1 results in misspli-
cing of the COL11A1 transcript. The silent c.2607A>G,
p.Ala869Ala mutation in family 3 resulted in three different
splice isoforms. First it was spliced normally, second the muta-
tion created a de novo donor splice site (as predicted by in silico
analysis) and third it also activated a pseudoexon in the preced-
ing intron. Both of the misspliced isoforms resulted in prema-
ture termination of the message and were only detected after
inhibition of nonsense mediated decay. The effect of this muta-
tion is to reduce the level of expression of the mutant allele,
without resulting in a null allele. Unlike in families 1 and 2,
where naturally occurring alternative splicing removes the muta-
tion from certain tissues, here it was variation caused by the
mutation that modified the phenotype. It is possible that the
proportion of the various isoforms may differ from tissue to
tissue, depending upon the expression of transacting splicing
factors, but this has not been investigated.
C-propeptide mutation
Family 3 also had a novel C-propeptide mutation, changing a con-
served glycine residue and incorporating an extra cysteine into the
C-propeptide. This domain of the fibrillar collagens has a highly
conserved pattern of cysteine residues which are important in
forming intramolecular and intermolecular disulphide bonds
during the trimerisation process of a collagen molecule.38 39
Although mutations in the C-propeptide of other fibrillar col-
lagens have been described, this is the first example of a
C-propeptide mutation in α1(XI) collagen. In other collagens,
mutations within this domain can produce a wide variety of phe-
notypes depending upon how they affect its folding and func-
tion.32 It is likely that this extra cysteine will disrupt this process,
as do similar mutations, that also create additional cysteines in the
C-propeptides of α1(I) and α1(II) collagens.40–42 Along with the
silent mutation c.2607A>G, p.Ala869Ala, inherited from the
father, they result in Stickler syndrome. Because the silent muta-
tion can also be spliced normally, it is not clear what phenotype
would result if this novel C-propeptide mutation had been inher-
ited with a null allele.
In summary, the identification here of a recessive form of
type 2 Stickler syndrome, associated with unusually profound
hearing loss, highlights the necessity for a detailed examination
of both parents and a detailed gene analysis. It should not be
assumed that a glycine substitution in the α1(XI) collagen helix
is dominant and the sole pathogenic cause of type 2 Stickler
syndrome. Of the 77 type 2 Stickler patients, with characterised
dominant mutations seen in our clinic, none had profound (ie,
greater than 95 dB) hearing loss (unpublished data), which
agrees with the recent review by Acke et al.18 In this respect,
families 1 and 2 were distinctive in their profound hearing loss,
which may be an indication that it is associated with a recessive
mode of inheritance.
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